AMNEAL PHARMACEUTICALS INC (AMRX) Stock News
NASDAQ:AMRX - Nasdaq - US03168L1052 - Common Stock - Currency: USD
AMRX Latest News, Press Releases and Analysis
Amneal to Report Fourth Quarter and Full Year 2024 Results on February 28, 2025
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions.
Amneal to Participate at Upcoming Investor Conferences
Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist
Amneal Reports Third Quarter 2024 Financial Results
Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
Amneal to Report Third Quarter 2024 Results on November 8, 2024
Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Amneal Launches CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
Amneal and Shilpa Announce U.S. FDA Approval of BORUZU™, the First Ready-to-Use Version of Bortezomib for subcutaneous administration
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amneal Pharmaceuticals (NASDAQ:AMRX) just reported results for the second quart...
Amneal Reports Second Quarter 2024 Financial Results
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
Amneal to Report Second Quarter 2024 Results on August 9, 2024
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
Amneal Releases 2023 Environmental, Social and Governance Report
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
Here are three stocks to buy up 100% in the past year. Make sure you add these to your portfolio so that you can reap the benefits.
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
Amneal to Participate at Upcoming Investor Conference
Amneal Begins Supplying Over-the-Counter Naloxone Hydrochloride Nasal Spray to U.S. Retail Pharmacies and the State of California
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics.
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amneal Pharmaceuticals (NYSE:AMRX) just reported results for the first quarter ...
Amneal Reports First Quarter 2024 Financial Results
